Cantor Fitzgerald Initiates Coverage on Nuvectis Pharma (NASDAQ:NVCT)

Equities researchers at Cantor Fitzgerald started coverage on shares of Nuvectis Pharma (NASDAQ:NVCT) in a report released on Monday, Marketbeat Ratings reports. The firm set an “overweight” rating on the stock.

A number of other equities analysts have also weighed in on the stock. UBS Group set a $33.00 price objective on shares of Nuvectis Pharma in a report on Monday, July 6th. Weiss Ratings upgraded Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. HC Wainwright lifted their target price on Nuvectis Pharma from $13.00 to $39.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Roth Capital boosted their price target on Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Finally, Wall Street Zen raised Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvectis Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $23.56 on Monday. The company has a market capitalization of $767.58 million, a price-to-earnings ratio of -17.98 and a beta of -0.26. Nuvectis Pharma has a one year low of $5.55 and a one year high of $29.27. The company’s 50-day moving average is $19.53 and its 200 day moving average is $12.78.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). As a group, research analysts predict that Nuvectis Pharma will post -0.98 earnings per share for the current fiscal year.

Insider Activity

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were bought at an average price of $18.32 per share, with a total value of $916,000.00. Following the completion of the acquisition, the insider owned 3,186,576 shares in the company, valued at $58,378,072.32. This represents a 1.59% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ron Bentsur bought 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were acquired at an average price of $20.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the chief executive officer directly owned 3,688,424 shares of the company’s stock, valued at $73,768,480. This trade represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 28.55% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Occam Crest Management LP raised its stake in Nuvectis Pharma by 31.0% during the 4th quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock worth $2,869,000 after acquiring an additional 90,000 shares during the period. Oppenheimer & Co. Inc. boosted its position in shares of Nuvectis Pharma by 6.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock worth $555,000 after purchasing an additional 4,500 shares during the period. Bank of America Corp DE purchased a new stake in shares of Nuvectis Pharma in the second quarter worth $218,000. Legal & General Group Plc purchased a new stake in shares of Nuvectis Pharma in the second quarter worth $31,000. Finally, BlackRock Inc. bought a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at $18,414,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.